Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Before beginning, verify the information, research side effects, and consult with your physician
Microchem J
Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
An integrated approach has been used to solubilize four highly hydrophobic polypeptides, viz
Ceruloplasmin dysfunction and therapeutic potential for parkinson disease
US$ 22.78
US$ 22.33
US$ 23.49
US$ 22.94
US$ 24.93
